Skip to main content
SpringerLink
Log in

Alemtuzumab

Lack of efficacy

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Lapucci C, et al. A real life, multicenter, observational study to evaluate safety and efficacy of the switch from alemtuzumab to ocrelizumab in MS patient with evidence of disease activity after two alemtuzumab courses: the italian experience. Multiple Sclerosis Journal 29 (Suppl. 3): 441-442 abstr. P466, Oct 2023. Available from: URL: https://dx.doi.org/10.1177/1352458523 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab. Reactions Weekly 2002, 29 (2024). https://doi.org/10.1007/s40278-024-55406-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-55406-3

Search

Navigation